Import and Export Controls on Synthetic Cannabinoid Extended
The Drug Enforcement Administration has issued a final rule extending through Feb. 5, 2019, the placement of the synthetic cannabinoid N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (MAB-CHMINACA), including its optical, positional, and geometric isomers, salts, and salts of isomers, into schedule I of the Controlled Substances Act. This rule continues the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (import, export, manufacture, distribute, engage in research, conduct instructional activities or chemical analysis, or possess) this substance, which include the following.
- all importation and exportation must continue to be in compliance with 21 USC 952, 953, 957, and 958 and in accordance with 21 CFR part 1312
- any activity involving this substance that is not authorized by, or is in violation of, the Controlled Substances Act or its implementing regulations continues to be unlawful and may subject the person to administrative, civil, or criminal sanctions
- any person who handles or desires to handle this substance must be registered with the DEA to conduct such activities
- all labels, labeling, and packaging for commercial containers of this substance must comply with 21 USC 825 and 958(e) and be in accordance with 21 CFR part 1302
- only registered manufacturers are permitted to manufacture this substance in accordance with an assigned quota
- every DEA registrant that possesses any quantity of this substance must take an inventory of all stocks on hand as of Oct. 16